# US 2020/0399348 A1 · HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399348 A1
- Document ID: US20200399348A1
- Status: Published application
- Kind: A1
- Application number: 16/971,627
- Filed: 2019-02-20
- Published: 2020-12-24
- Earliest claimed: 2018-02-20
- Assignees: Emory University
- Applicants: Emory University
- Inventors: Andreas Wieland; Rafi Ahmed
- Web page: https://patentgrep.com/patent/US20200399348A1

## CPC

- A61K 39/12: Viral antigens
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- A61K 38/2013: {IL-2}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/46: Viral antigens
- C07K 14/005: from viruses
- C12N 5/0636: {T lymphocytes}
- G01N 33/56983: {Viruses}
- G01N 33/575: for cancer
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C12N 2510/00: Genetically modified cells
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This disclosure relates to HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth. In certain embodiments, this disclosure relates to detecting an HPV protein in a sample and correlating the presence as an indication that a subject is at risk of developing an HPV-related disease or condition. In certain embodiments, the HPV protein is E2 and/or E6. In certain embodiments, this disclosure relates to vaccinating or treating a subject for an HPV infection or related condition optionally in combination with immune-checkpoint inhibitors. In certain embodiments, this disclosure relates to HPV protein specific antibodies and binding agents for uses reported herein.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of treating or preventing cancer comprising:
removing T cells from the blood of a subject;
replicating the T cells outside the body providing replicated T cells;
exposing the replicated T cells to a vector for expressing a chimeric antigen receptor on the surface of the cells, wherein the chimeric antigen receptor binds to HPV E2 providing HPV E2 targeted T-cells; and
administering HPV E2 targeted T cells to the subject in need thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the HPV E2 targeted T cells are administered in combination with IL-2.

### Claim 13 (depends on 11)

The method of claim 11, wherein the HPV E2 targeted T cells are administered in combination with an anti-CTLA4 or anti-PD1/PD-L1 antibody.

### Claim 14

A chimeric antibody that specifically binds HPV16 E2 protein.

### Claim 15 (depends on 14)

The chimeric antibody of claim 14 which is 22E2-B9.

### Claim 16 (depends on 14)

The chimeric antibody of claim 14 which is 22E2-F10.

### Claim 17 (depends on 14)

The chimeric antibody of claim 14 which is 22E2-05.

### Claim 18 (depends on 14)

The chimeric antibody of claim 14 which is 22E2-B8.

### Claim 19

A chimeric antibody that specifically binds HPV16 E6 protein.

### Claim 20 (depends on 19)

The chimeric antibody of claim 19 selected from 21-1E2, 21-1E11, and 21-1H3.